Market Overview
The China pharmaceutical market was valued at USD 306.5 Billion in 2024. It is projected to grow at a CAGR of 7.20% during the forecast period from 2025 to 2033, reaching a market size of USD 573.0 Billion by 2033. This growth is supported by factors such as a rising geriatric population, increasing healthcare facilities, and the prevalence of chronic diseases.
Study Assumption Years
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
China Pharmaceutical Market Key Takeaways
- Current Market Size: USD 306.5 Billion in 2024
- CAGR: 7.20% during 2025-2033
- Forecast Period: 2025-2033
- The market is driven by a rising geriatric population susceptible to chronic diseases such as diabetes, arthritis, and cardiovascular issues.
- The number of healthcare facilities like hospitals in China was 39,000 units in 2023, facilitating increased pharmaceutical consumption.
- Chinese pharmaceutical companies are expanding their global presence across Europe, Southeast Asia, and Latin America with strategic alliances and licensing deals.
- Digital drug sales are growing rapidly through online platforms like JD Health and Alibaba Health, enhancing medicine accessibility.
- Artificial intelligence is accelerating drug discovery and development, with companies using machine learning models for early-stage pharmaceutical R&D.
Sample Request Link:
https://www.imarcgroup.com/china-pharmaceutical-market/requestsample
Market Growth Factors
China's aging population is another reason that the pharmaceutical industry will continue to grow․ As people age, they are more likely to develop diabetes, heart diseases, and cancer․ Therefore, pharmaceutical firms are working on drugs specifically for the elderly with easier ways to administer drugs, less side effects, and more effective treatment for age-related diseases․ There are also low-cost drugs being developed to make medicines more affordable and the China pharmaceutical market in 2024 reflected the strong demand growth, considering the demographic trends occurring․
In addition, the growth of the markets is supported by the increasing number of hospitals in China․ According to CEIC, the number of hospitals in China increased to 39,000 in 2023 from 2022․ These healthcare facilities admit patients who have a wide range of diseases and health conditions, so the demand for pharmaceuticals in the hospitals is not uniform․ A full range of pharmaceuticals are prescribed by healthcare providers․ Government initiatives also can include the purchase of new machines and medical equipment, tax exemptions, incentives, and services provided to biotech incubators and startups, in addition to continuing to ease public private investment in the sector․
Years of investment in generics and biosimilars have enabled Chinese pharmaceutical companies to expand into markets across Europe, Southeast Asia and Latin America․ Formation of licensing, acquisition and collaboration partnerships helps reduce the time it takes for the US FDA and Europe-based EMA to approve the regulatory filings․ The state-owned and private companies are focused on exporting products in oncology, autoimmune and metabolic disease areas․ Their participation in international conferences and clinical trial networks indicates they focus on internationalization to increase revenues and contribute to their credibility and capabilities for innovation․
Market Segmentation
Type Insights:
- Pharmaceutical Drugs: This segment includes cardiovascular, dermatology, gastrointestinal, genito-urinary, hematology, anti-infective, metabolic disorder, musculoskeletal disorder, central nervous system, oncology, ophthalmology, and respiratory diseases drugs. These categories represent the broad spectrum of pharmaceutical medications manufactured and sold in China.
- Biologics: Encompasses monoclonal antibodies (MAbS), therapeutic proteins, and vaccines. These biologic products are gaining significant traction in China for targeted and precision therapies.
Nature Insights:
- Organic: Includes pharmaceutical products derived from natural sources or using organic manufacturing processes.
- Conventional: Covers traditional pharmaceutical products manufactured using standard chemical synthesis and processes.
Region Insights:
- North China
- East China
- South Central China
- Southwest China
- Northwest China
- Northeast China
These regions represent the major markets in China analyzed for pharmaceutical consumption and development.
Request Customization:
https://www.imarcgroup.com/request?type=report&id=23447&flag=E
Regional Insights
The report identifies multiple key regions within China, including North China, East China, South Central China, Southwest China, Northwest China, and Northeast China. Although detailed market share statistics are not provided, the segmentation underscores the broad geographic coverage and regional diversification of the pharmaceutical market throughout China.
Recent Developments & News
- On 01 August 2025, Ascentage Pharma announced plans to participate in the Evercore China Biotech Summit in Shanghai, featuring management engagements and an investor fireside chat.
- On 28 July 2025, Neuco United and Fosun Pharma executed an exclusive licensing deal for AR1001, an Alzheimer's therapy in Phase III trials, leveraging Fosun's manufacturing and commercial strengths in Greater China.
- On 20 March 2024, Sinopharm formed a strategic cooperation agreement with Fresenius Kabi (China) Co Ltd to expand pharma sales, warehousing, healthcare, and wellness services.
- On 30 October 2023, Jiangsu Hengrui Pharmaceuticals Co. Ltd. partnered with Merck to license and commercialize next-generation PARP1 inhibitor HRS-1167 and Claudin-18.2 antibody-drug conjugate SHR-A1904 worldwide.
Key Players
- Ascentage Pharma
- Neuco United
- Fosun Pharma
- AriBio
- Sinopharm
- Fresenius Kabi (China) Co Ltd
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Merck
Customization Note
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302